Investigation of Pharmacokinetic Properties of Single Subcutaneous Doses of NNC0174-0833 in Chinese Male Subjects Being Normal Weight, Overweight or With Obesity
Latest Information Update: 28 Nov 2022
At a glance
- Drugs Cagrilintide (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 21 Oct 2022 Status changed from recruiting to completed.
- 23 Mar 2022 Status changed from not yet recruiting to recruiting.
- 25 Feb 2022 New trial record